OncoMatch/Clinical Trials/NCT03537482
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
Is NCT03537482 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies APG-2575 for hematologic malignancies.
Treatment: APG-2575 — This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: allogeneic cell transplant
Lab requirements
Blood counts
Adequate bone marrow function independent of growth factor: ANC ≥1.0 X 10^9/L; Hemoglobin ≥ 8.0 g/dL; Platelets count ≥ 30 X 10^9/L (entry platelet count must be independent of transfusion within 7 days of first dose)
Kidney function
Adequate renal function as indicated by protocol
Liver function
Adequate liver function as indicated by protocol
Cardiac function
QTc interval ≤450ms in males, and ≤470ms in females
Adequate bone marrow function independent of growth factor: ANC ≥1.0 X 10^9/L; Hemoglobin ≥ 8.0 g/dL; Platelets count ≥ 30 X 10^9/L (entry platelet count must be independent of transfusion within 7 days of first dose). Adequate renal and liver function as indicated by protocol. QTc interval ≤450ms in males, and ≤470ms in females.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic · Jacksonville, Florida
- Duke Unviersity · Durham, North Carolina
- MDACC · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03537482 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic cell transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify